For a female liver transplant recipient more than five years post‑transplant who is taking tacrolimus 1 mg twice daily and has a trough level of 4.4 ng/mL, is this level acceptable and what adjustments, if any, are recommended?

Tacrolimus Level of 4.4 ng/mL is Acceptable in This Long-Term Liver Transplant Recipient

For a patient more than 5 years post-liver transplant on tacrolimus monotherapy, a trough level of 4.4 ng/mL falls within the acceptable range of 4-6 ng/mL recommended for long-term maintenance, and no dose adjustment is required unless there are specific clinical concerns. 1

Guideline-Based Target Ranges

The 2024 EASL guidelines provide clear stratification of tacrolimus targets based on time post-transplant 1:

• First month: 6-10 ng/mL
• After first month: 4-8 ng/mL
• Beyond first year: 4-6 ng/mL for monotherapy

Your patient at >5 years post-transplant with a level of 4.4 ng/mL sits comfortably within the recommended 4-6 ng/mL range for long-term maintenance on tacrolimus monotherapy.

Clinical Reasoning

Why this level is appropriate:

• Reduced rejection risk: Beyond 5 years post-transplant, the risk of acute cellular rejection is substantially lower, allowing for lower immunosuppression targets 1
• Renal protection: Lower tacrolimus levels minimize calcineurin inhibitor nephrotoxicity, which is critical for long-term kidney function preservation 1, 2
• Reduced side effects: Lower exposure decreases risks of hypertension, diabetes, neurotoxicity, and malignancy 1

Important Caveats and Monitoring

Do NOT reduce the dose further without:

1. Checking for donor-specific antibodies (DSAs): The guidelines explicitly warn that some long-term survivors maintain normal liver tests with levels below 4 ng/mL, but this carries risk of subclinical rejection 1

2. Monitoring liver enzymes closely: Ensure ALT/AST remain stable at current levels

3. Consider transient elastography: To detect subclinical fibrosis that might indicate inadequate immunosuppression 1

Red flags that would require intervention:

• Rising liver enzymes (ALT, AST, alkaline phosphatase)
• Development of de novo DSAs
• Increasing liver stiffness on elastography
• Any clinical signs of rejection

When Lower Levels Might Be Considered

If this patient were on combination therapy (tacrolimus + mycophenolate mofetil or mTOR inhibitor), even lower targets of 3-5 ng/mL would be acceptable 1. Consider adding a second agent if:

• Renal function is deteriorating (rising creatinine)
• History of skin cancer or high malignancy risk
• Significant tacrolimus-related side effects

Common Pitfall to Avoid

Do not reflexively increase the dose simply because 4.4 ng/mL seems "low" compared to early post-transplant targets. The guidelines are explicit that long-term stable patients require lower levels. Unnecessary increases expose patients to avoidable nephrotoxicity and other complications without added benefit 1, 3.

The current level of 4.4 ng/mL represents appropriate, evidence-based immunosuppression for a patient >5 years post-liver transplant on tacrolimus monotherapy, assuming stable graft function and absence of DSAs.